11-oxyandrogen Concentrations in Adolescents With Polycystic Ovary Syndrome (PCOS)

PCOS is common in adolescents and includes excess testosterone concentrations. The clinical importance of 11-oxyandrogens in PCOS is unclear. We sought to determine if fasted morning 11-oxyandrogens: 1) better identify PCOS diagnosis compared to testosterone, 2) relate to clinical comorbidities of P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Endocrine Society 2021-05, Vol.5 (Supplement_1), p.A736-A737
Hauptverfasser: Taylor, Anya, Ware, Meredith A, Breslow, Emily, Pyle, Laura, Severn, Cameron, Chan, Christine L, Kelsey, Megan Moriarty, Cree-Green, Melanie
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A737
container_issue Supplement_1
container_start_page A736
container_title Journal of the Endocrine Society
container_volume 5
creator Taylor, Anya
Ware, Meredith A
Breslow, Emily
Pyle, Laura
Severn, Cameron
Chan, Christine L
Kelsey, Megan Moriarty
Cree-Green, Melanie
description PCOS is common in adolescents and includes excess testosterone concentrations. The clinical importance of 11-oxyandrogens in PCOS is unclear. We sought to determine if fasted morning 11-oxyandrogens: 1) better identify PCOS diagnosis compared to testosterone, 2) relate to clinical comorbidities of PCOS, 3) are altered with combined oral contraceptive pill (COCP) or metformin therapy. Data from 186 adolescent females aged 12-21 years, mostly obese, enrolled in one of 6 studies in our division were included: 115 untreated PCOS (13 lean, BMI 22.5±2.2 kg/m2; 102 overweight/obese, BMI 35.4±5.3), 9 obese PCOS treated with COCP (BMI 33.7±5.7), 6 obese PCOS treated with metformin (BMI 36.4±5.3) and 70 normally cycling controls (19 lean, BMI 19.9±1.4; 52 overweight/obese BMI 35.5±10.4). Three 11-oxyandrogens (11-hydroxyandrostenedione (11OHA), 11-hydroxytestosterone (11OHT), and 11-ketotestosterone (11KT) and total testosterone were analyzed via liquid chromatography tandem mass spectroscopy (LabCorp/Esoterix, Calabasas, CA). Data between 1) untreated PCOS and controls and 2) untreated PCOS and the 2 treatment groups were compared. ROC analysis was performed to evaluate accuracy of diagnosis of PCOS and Pearson’s correlation coefficient was calculated for 11-oxyandrogens and clinical measures. Untreated PCOS girls had higher 11OHA (129±77 ng/dL PCOS vs 97±52 control, p=0.003) and 11OHT (13.8±7.9 ng/dL PCOS vs 10.5±6.7 control, p=0.005) compared to controls, with no difference in 11KT (30.7±17.3 ng/dL PCOS vs 26.6±16.6 control, p=0.208). Only 11OHA remained significant after controlling for obesity via multiple linear regression. However, neither of these metabolites better predicted PCOS status compared to testosterone (ROC analysis: 11OHA AUC=0.620, p=0.006; 11OHT AUC=0.638, p=0.002; total testosterone AUC=0.840, p
doi_str_mv 10.1210/jendso/bvab048.1498
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1210_jendso_bvab048_1498</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1210_jendso_bvab048_1498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c898-9f705b3da78060ece45590cd6152db1892648b4e361014064aa7089d9a053e4f3</originalsourceid><addsrcrecordid>eNpNkD1rwzAYhEVpoSHNL-iisR2cvK8k29IYTL8g4NAEOhpZklsHRyqWCfW_b00ydLrj4I7jIeQeYYkMYXVw3sawqk-6BiGXKJS8IjMmcpagytn1P39LFjEeAAAVF0qIGXlHTMLPqL3tw6fztAjeOD_0emiDj7T1dG1D5-IURvrRDl90G7rRjHFoDS1Puh_pbpzaR0cftkW5e7wjN43uoltcdE72z0_74jXZlC9vxXqTGKlkopoc0ppbnUvIwBkn0lSBsRmmzNYoFcuErIXjGQIKyITWOUhllYaUO9HwOeHnWdOHGHvXVN99e_z7UyFUE5jqDKa6gKkmMPwXbOhYxA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>11-oxyandrogen Concentrations in Adolescents With Polycystic Ovary Syndrome (PCOS)</title><source>Oxford Journals Open Access Collection</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Taylor, Anya ; Ware, Meredith A ; Breslow, Emily ; Pyle, Laura ; Severn, Cameron ; Chan, Christine L ; Kelsey, Megan Moriarty ; Cree-Green, Melanie</creator><creatorcontrib>Taylor, Anya ; Ware, Meredith A ; Breslow, Emily ; Pyle, Laura ; Severn, Cameron ; Chan, Christine L ; Kelsey, Megan Moriarty ; Cree-Green, Melanie</creatorcontrib><description>PCOS is common in adolescents and includes excess testosterone concentrations. The clinical importance of 11-oxyandrogens in PCOS is unclear. We sought to determine if fasted morning 11-oxyandrogens: 1) better identify PCOS diagnosis compared to testosterone, 2) relate to clinical comorbidities of PCOS, 3) are altered with combined oral contraceptive pill (COCP) or metformin therapy. Data from 186 adolescent females aged 12-21 years, mostly obese, enrolled in one of 6 studies in our division were included: 115 untreated PCOS (13 lean, BMI 22.5±2.2 kg/m2; 102 overweight/obese, BMI 35.4±5.3), 9 obese PCOS treated with COCP (BMI 33.7±5.7), 6 obese PCOS treated with metformin (BMI 36.4±5.3) and 70 normally cycling controls (19 lean, BMI 19.9±1.4; 52 overweight/obese BMI 35.5±10.4). Three 11-oxyandrogens (11-hydroxyandrostenedione (11OHA), 11-hydroxytestosterone (11OHT), and 11-ketotestosterone (11KT) and total testosterone were analyzed via liquid chromatography tandem mass spectroscopy (LabCorp/Esoterix, Calabasas, CA). Data between 1) untreated PCOS and controls and 2) untreated PCOS and the 2 treatment groups were compared. ROC analysis was performed to evaluate accuracy of diagnosis of PCOS and Pearson’s correlation coefficient was calculated for 11-oxyandrogens and clinical measures. Untreated PCOS girls had higher 11OHA (129±77 ng/dL PCOS vs 97±52 control, p=0.003) and 11OHT (13.8±7.9 ng/dL PCOS vs 10.5±6.7 control, p=0.005) compared to controls, with no difference in 11KT (30.7±17.3 ng/dL PCOS vs 26.6±16.6 control, p=0.208). Only 11OHA remained significant after controlling for obesity via multiple linear regression. However, neither of these metabolites better predicted PCOS status compared to testosterone (ROC analysis: 11OHA AUC=0.620, p=0.006; 11OHT AUC=0.638, p=0.002; total testosterone AUC=0.840, p&lt;0.001, free androgen index AUC 0.860, p&lt;0.001). Among girls with PCOS, all three 11-oxyandrogens correlated with hirsutism severity as graded by Ferriman Gallwey score. COCP treatment decreased 11KT concentrations compared to untreated PCOS (32±17 untreated vs 17±8 ng/dL COCP; p=0.039) as well as total testosterone (46.9±21 untreated vs 28.1±12.9 ng/dL COCP; p&lt;0.006). However, metformin treatment had no effect 11-oxyandrogens, although total testosterone was lower (46.9±21 untreated vs 26.5±5.9 metformin; p=0.01). Whereas 11-oxyandrogens would not aid in the diagnosis of PCOS, they relate to excess hair growth and 11KT decreases with COCP therapy. Further work is needed to determine the relationship with metabolic outcomes and the clinical utility of measuring these androgens in PCOS.</description><identifier>ISSN: 2472-1972</identifier><identifier>EISSN: 2472-1972</identifier><identifier>DOI: 10.1210/jendso/bvab048.1498</identifier><language>eng</language><ispartof>Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A736-A737</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Taylor, Anya</creatorcontrib><creatorcontrib>Ware, Meredith A</creatorcontrib><creatorcontrib>Breslow, Emily</creatorcontrib><creatorcontrib>Pyle, Laura</creatorcontrib><creatorcontrib>Severn, Cameron</creatorcontrib><creatorcontrib>Chan, Christine L</creatorcontrib><creatorcontrib>Kelsey, Megan Moriarty</creatorcontrib><creatorcontrib>Cree-Green, Melanie</creatorcontrib><title>11-oxyandrogen Concentrations in Adolescents With Polycystic Ovary Syndrome (PCOS)</title><title>Journal of the Endocrine Society</title><description>PCOS is common in adolescents and includes excess testosterone concentrations. The clinical importance of 11-oxyandrogens in PCOS is unclear. We sought to determine if fasted morning 11-oxyandrogens: 1) better identify PCOS diagnosis compared to testosterone, 2) relate to clinical comorbidities of PCOS, 3) are altered with combined oral contraceptive pill (COCP) or metformin therapy. Data from 186 adolescent females aged 12-21 years, mostly obese, enrolled in one of 6 studies in our division were included: 115 untreated PCOS (13 lean, BMI 22.5±2.2 kg/m2; 102 overweight/obese, BMI 35.4±5.3), 9 obese PCOS treated with COCP (BMI 33.7±5.7), 6 obese PCOS treated with metformin (BMI 36.4±5.3) and 70 normally cycling controls (19 lean, BMI 19.9±1.4; 52 overweight/obese BMI 35.5±10.4). Three 11-oxyandrogens (11-hydroxyandrostenedione (11OHA), 11-hydroxytestosterone (11OHT), and 11-ketotestosterone (11KT) and total testosterone were analyzed via liquid chromatography tandem mass spectroscopy (LabCorp/Esoterix, Calabasas, CA). Data between 1) untreated PCOS and controls and 2) untreated PCOS and the 2 treatment groups were compared. ROC analysis was performed to evaluate accuracy of diagnosis of PCOS and Pearson’s correlation coefficient was calculated for 11-oxyandrogens and clinical measures. Untreated PCOS girls had higher 11OHA (129±77 ng/dL PCOS vs 97±52 control, p=0.003) and 11OHT (13.8±7.9 ng/dL PCOS vs 10.5±6.7 control, p=0.005) compared to controls, with no difference in 11KT (30.7±17.3 ng/dL PCOS vs 26.6±16.6 control, p=0.208). Only 11OHA remained significant after controlling for obesity via multiple linear regression. However, neither of these metabolites better predicted PCOS status compared to testosterone (ROC analysis: 11OHA AUC=0.620, p=0.006; 11OHT AUC=0.638, p=0.002; total testosterone AUC=0.840, p&lt;0.001, free androgen index AUC 0.860, p&lt;0.001). Among girls with PCOS, all three 11-oxyandrogens correlated with hirsutism severity as graded by Ferriman Gallwey score. COCP treatment decreased 11KT concentrations compared to untreated PCOS (32±17 untreated vs 17±8 ng/dL COCP; p=0.039) as well as total testosterone (46.9±21 untreated vs 28.1±12.9 ng/dL COCP; p&lt;0.006). However, metformin treatment had no effect 11-oxyandrogens, although total testosterone was lower (46.9±21 untreated vs 26.5±5.9 metformin; p=0.01). Whereas 11-oxyandrogens would not aid in the diagnosis of PCOS, they relate to excess hair growth and 11KT decreases with COCP therapy. Further work is needed to determine the relationship with metabolic outcomes and the clinical utility of measuring these androgens in PCOS.</description><issn>2472-1972</issn><issn>2472-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkD1rwzAYhEVpoSHNL-iisR2cvK8k29IYTL8g4NAEOhpZklsHRyqWCfW_b00ydLrj4I7jIeQeYYkMYXVw3sawqk-6BiGXKJS8IjMmcpagytn1P39LFjEeAAAVF0qIGXlHTMLPqL3tw6fztAjeOD_0emiDj7T1dG1D5-IURvrRDl90G7rRjHFoDS1Puh_pbpzaR0cftkW5e7wjN43uoltcdE72z0_74jXZlC9vxXqTGKlkopoc0ppbnUvIwBkn0lSBsRmmzNYoFcuErIXjGQIKyITWOUhllYaUO9HwOeHnWdOHGHvXVN99e_z7UyFUE5jqDKa6gKkmMPwXbOhYxA</recordid><startdate>20210503</startdate><enddate>20210503</enddate><creator>Taylor, Anya</creator><creator>Ware, Meredith A</creator><creator>Breslow, Emily</creator><creator>Pyle, Laura</creator><creator>Severn, Cameron</creator><creator>Chan, Christine L</creator><creator>Kelsey, Megan Moriarty</creator><creator>Cree-Green, Melanie</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20210503</creationdate><title>11-oxyandrogen Concentrations in Adolescents With Polycystic Ovary Syndrome (PCOS)</title><author>Taylor, Anya ; Ware, Meredith A ; Breslow, Emily ; Pyle, Laura ; Severn, Cameron ; Chan, Christine L ; Kelsey, Megan Moriarty ; Cree-Green, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c898-9f705b3da78060ece45590cd6152db1892648b4e361014064aa7089d9a053e4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, Anya</creatorcontrib><creatorcontrib>Ware, Meredith A</creatorcontrib><creatorcontrib>Breslow, Emily</creatorcontrib><creatorcontrib>Pyle, Laura</creatorcontrib><creatorcontrib>Severn, Cameron</creatorcontrib><creatorcontrib>Chan, Christine L</creatorcontrib><creatorcontrib>Kelsey, Megan Moriarty</creatorcontrib><creatorcontrib>Cree-Green, Melanie</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of the Endocrine Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, Anya</au><au>Ware, Meredith A</au><au>Breslow, Emily</au><au>Pyle, Laura</au><au>Severn, Cameron</au><au>Chan, Christine L</au><au>Kelsey, Megan Moriarty</au><au>Cree-Green, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>11-oxyandrogen Concentrations in Adolescents With Polycystic Ovary Syndrome (PCOS)</atitle><jtitle>Journal of the Endocrine Society</jtitle><date>2021-05-03</date><risdate>2021</risdate><volume>5</volume><issue>Supplement_1</issue><spage>A736</spage><epage>A737</epage><pages>A736-A737</pages><issn>2472-1972</issn><eissn>2472-1972</eissn><abstract>PCOS is common in adolescents and includes excess testosterone concentrations. The clinical importance of 11-oxyandrogens in PCOS is unclear. We sought to determine if fasted morning 11-oxyandrogens: 1) better identify PCOS diagnosis compared to testosterone, 2) relate to clinical comorbidities of PCOS, 3) are altered with combined oral contraceptive pill (COCP) or metformin therapy. Data from 186 adolescent females aged 12-21 years, mostly obese, enrolled in one of 6 studies in our division were included: 115 untreated PCOS (13 lean, BMI 22.5±2.2 kg/m2; 102 overweight/obese, BMI 35.4±5.3), 9 obese PCOS treated with COCP (BMI 33.7±5.7), 6 obese PCOS treated with metformin (BMI 36.4±5.3) and 70 normally cycling controls (19 lean, BMI 19.9±1.4; 52 overweight/obese BMI 35.5±10.4). Three 11-oxyandrogens (11-hydroxyandrostenedione (11OHA), 11-hydroxytestosterone (11OHT), and 11-ketotestosterone (11KT) and total testosterone were analyzed via liquid chromatography tandem mass spectroscopy (LabCorp/Esoterix, Calabasas, CA). Data between 1) untreated PCOS and controls and 2) untreated PCOS and the 2 treatment groups were compared. ROC analysis was performed to evaluate accuracy of diagnosis of PCOS and Pearson’s correlation coefficient was calculated for 11-oxyandrogens and clinical measures. Untreated PCOS girls had higher 11OHA (129±77 ng/dL PCOS vs 97±52 control, p=0.003) and 11OHT (13.8±7.9 ng/dL PCOS vs 10.5±6.7 control, p=0.005) compared to controls, with no difference in 11KT (30.7±17.3 ng/dL PCOS vs 26.6±16.6 control, p=0.208). Only 11OHA remained significant after controlling for obesity via multiple linear regression. However, neither of these metabolites better predicted PCOS status compared to testosterone (ROC analysis: 11OHA AUC=0.620, p=0.006; 11OHT AUC=0.638, p=0.002; total testosterone AUC=0.840, p&lt;0.001, free androgen index AUC 0.860, p&lt;0.001). Among girls with PCOS, all three 11-oxyandrogens correlated with hirsutism severity as graded by Ferriman Gallwey score. COCP treatment decreased 11KT concentrations compared to untreated PCOS (32±17 untreated vs 17±8 ng/dL COCP; p=0.039) as well as total testosterone (46.9±21 untreated vs 28.1±12.9 ng/dL COCP; p&lt;0.006). However, metformin treatment had no effect 11-oxyandrogens, although total testosterone was lower (46.9±21 untreated vs 26.5±5.9 metformin; p=0.01). Whereas 11-oxyandrogens would not aid in the diagnosis of PCOS, they relate to excess hair growth and 11KT decreases with COCP therapy. Further work is needed to determine the relationship with metabolic outcomes and the clinical utility of measuring these androgens in PCOS.</abstract><doi>10.1210/jendso/bvab048.1498</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2472-1972
ispartof Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A736-A737
issn 2472-1972
2472-1972
language eng
recordid cdi_crossref_primary_10_1210_jendso_bvab048_1498
source Oxford Journals Open Access Collection; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
title 11-oxyandrogen Concentrations in Adolescents With Polycystic Ovary Syndrome (PCOS)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T08%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=11-oxyandrogen%20Concentrations%20in%20Adolescents%20With%20Polycystic%20Ovary%20Syndrome%20(PCOS)&rft.jtitle=Journal%20of%20the%20Endocrine%20Society&rft.au=Taylor,%20Anya&rft.date=2021-05-03&rft.volume=5&rft.issue=Supplement_1&rft.spage=A736&rft.epage=A737&rft.pages=A736-A737&rft.issn=2472-1972&rft.eissn=2472-1972&rft_id=info:doi/10.1210/jendso/bvab048.1498&rft_dat=%3Ccrossref%3E10_1210_jendso_bvab048_1498%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true